Patents Assigned to CLINICAL GENOMICS PTY. LTD.
-
Publication number: 20230212685Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.Type: ApplicationFiled: October 31, 2022Publication date: July 6, 2023Applicants: Quest Diagnostics Investments LLC, Clinical Genomics PTY LtdInventors: Susanne PEDERSEN, Lawrence LaPOINTE, Rohan BAKER, Amber C. DONAHUE, Yen-lin PENG, Frederic WALDMAN
-
Patent number: 11486007Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.Type: GrantFiled: June 3, 2015Date of Patent: November 1, 2022Assignees: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTDInventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
-
Patent number: 11254985Abstract: The present invention relates generally to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention relates to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for changes to the methylation levels of a panel of gene markers including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.Type: GrantFiled: May 10, 2013Date of Patent: February 22, 2022Assignees: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATIONInventors: Peter Molloy, Lawrence Lapointe, Susanne Pedersen
-
Patent number: 10941449Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.Type: GrantFiled: May 17, 2013Date of Patent: March 9, 2021Assignee: CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence Charles Lapointe, Susanne K. Pedersen, Rohan Baker, Snigdha Gaur, Melissa Thomas
-
Patent number: 10767214Abstract: The present invention relates to a method of enriching for membranous microvesicles relative to the cellular population in a biological sample. More particularly, there is provided a method for enriching for exosomes from plasma. In a related aspect, there is provided a method of reducing the concentration of cellular and cellular derived molecules in a biological sample. Still further, the present invention provides methods for selectively isolating mRNA subpopulations from exosomes. Yet further, there are provided methods of amplifying exosome derived RNA. The method of the present invention is useful in a range of applications including, but not limited to, diagnostic, prognostic, therapeutic, research and development applications, to the extent that the enrichment of exosomes is required.Type: GrantFiled: October 26, 2011Date of Patent: September 8, 2020Assignee: CLINICAL GENOMICS PTY LTDInventors: Lawrence Charles LaPointe, Susanne Kartin Pedersen, Aidan McEvoy
-
Patent number: 10590468Abstract: The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and RNA methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.Type: GrantFiled: June 1, 2015Date of Patent: March 17, 2020Assignee: CLINICAL GENOMICS PTY LTDInventors: Susanne Pedersen, Rohan Baker
-
Patent number: 10526642Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.Type: GrantFiled: August 24, 2012Date of Patent: January 7, 2020Assignees: Commonwealth Scientific and Industrial Research Organisation, Clinical Genomics Pty. Ltd.Inventors: Peter Laurence Molloy, Lawrence Charles Lapointe, Susanne Kartin Pedersen, Susan Margaret Mitchell
-
Patent number: 10344334Abstract: Disclosed are nucleic acid, RNA, and protein expression profiles which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly disclosed are nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenomas and adenocarcinomas. Further disclosed are methods of screening a subject for the onset, predisposition to the onset and/or progression of a large intestine neoplasm by screening for modulation in the expression profile of the disclosed nucleic acid molecule markers.Type: GrantFiled: August 12, 2015Date of Patent: July 9, 2019Assignees: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence Charles LaPointe, Robert Dunne, Graeme P. Young, Peter Molloy, Susanne Pedersen, Glenn Southwell Brown, Lloyd Douglas Graham
-
Publication number: 20190024188Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as a adenoma or an adeocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinoma.Type: ApplicationFiled: October 2, 2018Publication date: January 24, 2019Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence C. LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON, Peter Laurence MOLLOY
-
Publication number: 20180100200Abstract: The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.Type: ApplicationFiled: November 10, 2017Publication date: April 12, 2018Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence Charles LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON
-
Patent number: 9765397Abstract: The present invention relates to a method of screening for the presence of methylated DNA in a biological sample by using multiple methylation-sensitive restriction endonucleases. More particularly, the present invention relates to a method of quantitatively screening for the level of one or more methylated genes of interest without the requirement that an undigested internal reference sample is used as a point of reference against which relative quantification is calculated. The present invention is useful in a range of applications including, but not limited to, providing a simpler and more accurate means to determine DNA methylation status, such as in the context of diagnosing or monitoring conditions characterised by changes to DNA methylation.Type: GrantFiled: November 26, 2013Date of Patent: September 19, 2017Assignee: Clinical Genomics Pty LtdInventors: Aidan McEvoy, Susanne Pedersen, Rohan Baker
-
Publication number: 20170260585Abstract: The present invention relates generally to an array of nucleic acid molecules, the expression profiles of which characterise the anatomical origin of a cell or population of cells within the large intestine. More particularly, the present invention relates to an array of nucleic acid molecules, the expression profiles of which characterise the proximal or distal origin of a cell or population of cells within the large intestine. The expression profiles of the present invention are useful in a range of applications including, but not limited to determining the anatomical origin of a cell or population of cells which have been derived from the large intestine.Type: ApplicationFiled: February 22, 2017Publication date: September 14, 2017Applicants: Clinical Genomics Pty. Ltd., Commonwealth Scientific and Industrial Research OrganisationInventors: Lawrence C. LAPOINTE, Robert DUNNE
-
Publication number: 20170246626Abstract: Provided is a test device for testing an analyte in a collected sample comprising: an enclosure having at least one sample receiving port for receiving the sample; a test strip located within the enclosure, the test strip containing at least one reagent for detecting the analyte and for providing an indication showing a test result for the sample, the enclosure including a detection arrangement for allowing detection of the indication of the test strip; a sample receiving matrix positioned behind the at least one sample receiving port and having a defined saturation capacity, the sample receiving matrix being impregnated with reagents for pre-treatment of the sample and being in liquid conductive communication with the test strip.Type: ApplicationFiled: August 31, 2015Publication date: August 31, 2017Applicant: CLINICAL GENOMICS PTY LTDInventor: Howard Milne CHANDLER
-
Publication number: 20170191135Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.Type: ApplicationFiled: June 3, 2015Publication date: July 6, 2017Applicants: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTDInventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
-
Publication number: 20170145485Abstract: The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.Type: ApplicationFiled: June 1, 2015Publication date: May 25, 2017Applicant: CLINICAL GENOMICS PTY LTDInventors: Susanne PEDERSEN, Rohan BAKER
-
Publication number: 20160130657Abstract: The present invention relates generally to a nucleic acid molecule, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly, the present invention is directed to a nucleic acid molecule, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenomas and adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a large intestine neoplasm by screening for modulation in the expression profile of said nucleic acid molecule markers.Type: ApplicationFiled: August 12, 2015Publication date: May 12, 2016Applicants: CLINICAL GENOMICS PTY. LTD., COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Lawrence Charles LaPointe, Robert Dunne, Graeme P. Young, Peter Molloy, Susanne Pedersen, Glenn Southwell Brown, Lloyd Douglas Graham
-
Publication number: 20150152505Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.Type: ApplicationFiled: May 17, 2013Publication date: June 4, 2015Applicant: CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence Charles Lapointe, Susanne K. Pedersen, Rohan Baker, Snigdha Gaur, Melissa Thomas
-
Publication number: 20150010951Abstract: The present invention relates to a method of enriching for membranous microvesicles relative to the cellular population in a biological sample. More particularly, there is provided a method for enriching for exosomes from plasma. In a related aspect, there is provided a method of reducing the concentration of cellular and cellular derived molecules in a biological sample. Still further, the present invention provides methods for selectively isolating mRNA subpopulations from exosomes. Yet further, there are provided methods of amplifying exosome derived RNA. The method of the present invention is useful in a range of applications including, but not limited to, diagnostic, prognostic, therapeutic, research and development applications, to the extent that the enrichment of exosomes is required.Type: ApplicationFiled: October 26, 2011Publication date: January 8, 2015Applicant: Clinical Genomics Pty. Ltd.Inventors: Lawrence Charles LaPointe, Susanne Kartin Pedersen, Aidan McEvoy
-
Publication number: 20140315203Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.Type: ApplicationFiled: August 24, 2012Publication date: October 23, 2014Applicants: Commonwealth Scientific and Industrial Research Organisation, Clinical Genomics Pty. Ltd.Inventors: Peter Laurence Molloy, Lawrence Charles Lapointe, Susanne Kartin Pedersen, Susan Margaret Mitchell
-
Publication number: 20140287940Abstract: The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas.Type: ApplicationFiled: October 18, 2013Publication date: September 25, 2014Applicants: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, CLINICAL GENOMICS PTY. LTD.Inventors: Lawrence C. LAPOINTE, Robert DUNNE, Graeme P. YOUNG, Trevor John LOCKETT, William J. WILSON, Peter Laurence MOLLOY